Center-Authored Papers

Filters: Author is Tangen, Catherine M  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Chen H, Liu X, Brendler CB, Ankerst DP, Leach RJ, Goodman PJ, Lucia SM, Tangen CM, Wang L, Hsu F-C et al..  2016.  Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial.. The Prostate. 76(12):1120-1129. Abstract
Thompson IM, Tangen CM, Paradelo J, Lucia SM, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G et al..  2009.  Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial.. The Journal of urology. 181(3):956-62. Abstract
Hershman DL, Unger JM, Wright JD, Ramsey SD, Till C, Tangen CM, Barlow WE, Blanke C, Thompson IM, Hussain M.  2016.  Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer.. JAMA oncology. 2(4):453-61. Abstract
Gong Z, Kristal AR, Schenk JM, Tangen CM, Goodman PJ, Thompson IM.  2009.  Alcohol consumption, finasteride, and prostate cancer risk: results from the Prostate Cancer Prevention Trial.. Cancer. 115(16):3661-9. Abstract
Price DK, Chau CH, Till C, Goodman PJ, Baum CE, Ockers SB, English BC, Minasian L, Parnes HL, Hsing AW et al..  2010.  Androgen receptor CAG repeat length and association with prostate cancer risk: results from the prostate cancer prevention trial.. The Journal of urology. 184(6):2297-302. Abstract
Figg WD, Chau CH, Price DK, Till C, Goodman PJ, Cho Y, Varella-Garcia M, Reichardt JKV, Tangen CM, Leach RJ et al..  2014.  Androgen Receptor CAG Repeat Length and TMPRSS2:ETS Prostate Cancer Risk: Results From the Prostate Cancer Prevention Trial.. Urology. Abstract
Sartor OA, Tangen CM, Hussain MHA, Eisenberger MA, Parab M, Fontana JA, Chapman RA, Mills GM, Raghavan D, Crawford DE.  2008.  Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426).. Cancer. 112(11):2393-400. Abstract
Winchester DA, Till C, Goodman PJ, Tangen CM, Santella RM, Johnson-Pais TL, Leach RJ, Xu J, Zheng LS, Thompson IM et al..  2017.  Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial.. The Prostate. Abstract
Price DK, Chau CH, Till C, Goodman PJ, Leach RJ, Johnson-Pais TL, Hsing AW, Hoque A, Parnes HL, Schenk JM et al..  2016.  Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial.. Cancer. 122(15):2332-2340. Abstract
Schenk JM, Kristal AR, Arnold KB, Tangen CM, Neuhouser ML, Lin DW, White E, Thompson IM.  2011.  Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial.. American journal of epidemiology. 173(12):1419-28. Abstract
Kristal AR, Till C, Tangen CM, Goodman PJ, Neuhouser ML, Stanczyk FZ, Chu LW, Patel SK, Thompson IM, Reichardt JK et al..  2012.  Associations of Serum Sex Steroid Hormone and 5α-Androstane-3α,17β-Diol Glucuronide Concentrations with Prostate Cancer Risk Among Men Treated with Finasteride.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. Abstract
B
Kristal AR, Darke AK, Morris SJ, Tangen CM, Goodman PJ, Thompson IM, Meyskens FL, Goodman GE, Minasian LM, Parnes HL et al..  2014.  Baseline Selenium Status and Effects of Selenium and Vitamin E Supplementation on Prostate Cancer Risk.. Journal of the National Cancer Institute. Abstract
Tangen CM, Goodman PJ, Till C, Schenk JM, Lucia SM, Thompson IM.  2016.  Biases in Recommendations for and Acceptance of Prostate Biopsy Significantly Affect Assessment of Prostate Cancer Risk Factors: Results From Two Large Randomized Clinical Trials.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 34(36):4338-4344. Abstract
Schenk JM, Kristal AR, Neuhouser ML, Tangen CM, White E, Lin DW, Kratz M, Thompson IM.  2010.  Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.. American journal of epidemiology. 171(5):571-82. Abstract
C
Thompson IM, Tangen CM, Goodman PJ, Lucia SM, Klein EA.  2009.  Chemoprevention of prostate cancer.. The Journal of urology. 182(2):499-507;discussion508. Abstract
Gurel B, Lucia SM, Thompson IM, Goodman PJ, Tangen CM, Kristal AR, Parnes HL, Hoque A, Lippman SM, Sutcliffe S et al..  2014.  Chronic Inflammation in Benign Prostate Tissue Is Associated with High-Grade Prostate Cancer in the Placebo Arm of the Prostate Cancer Prevention Trial.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. Abstract
Crowe FL, Appleby PN, Travis RC, Barnett M, Brasky TM, Bueno-de-Mesquita BH, Chajes V, Chavarro JE, Chirlaque M-D, English DR et al..  2014.  Circulating fatty acids and prostate cancer risk: individual participant meta-analysis of prospective studies.. Journal of the National Cancer Institute. 106(9) Abstract
Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu T, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci MA et al..  2014.  Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Abstract
D
Huyghe JR, Bien SA, Harrison TA, Kang HM, Chen S, Schmit SL, Conti DV, Qu C, Jeon J, Edlund CK et al..  2018.  Discovery of common and rare genetic risk variants for colorectal cancer.. Nature genetics. Abstract
Scosyrev E, Ely BW, Messing EM, Speights VO, Grossman BH, Wood DP, deVere White RW, Vogelzang NJ, Trump DL, Natale RB et al..  2011.  Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710). BJU international. 108(5):693-699. Abstract
Quinn DI, Tangen CM, Hussain M, Lara PN, Goldkorn A, Moinpour CM, Garzotto MG, Mack PC, Carducci MA, Monk PJ et al..  2013.  Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.. The lancet oncology. 14(9):893-900. Abstract
Thompson IM, Tangen CM, Parnes HL, Lippman SM, Coltman CA.  2008.  Does the level of prostate cancer risk affect cancer prevention with finasteride? Urology. 71(5):854-7. Abstract
E
Hoque A, Yao S, Till C, Kristal AR, Goodman PJ, Hsing AW, Tangen CM, Platz EA, Stanczyk FZ, Reichardt JKV et al..  2015.  Effect of finasteride on serum androstenedione and risk of prostate cancer within the prostate cancer prevention trial: differential effect on high- and low-grade disease.. Urology. 85(3):616-20. Abstract
Vickers AJ, Till C, Tangen CM, Lilja H, Thompson IM.  2011.  An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.. Journal of the National Cancer Institute. 103(6):462-9. Abstract
Moodie PF, Saville BR, Koch GG, Tangen CM.  2011.  Estimating Covariate-Adjusted Log Hazard Ratios for Multiple Time Intervals in Clinical Trials Using Nonparametric Randomization Based ANCOVA. Statistics in Biopharmaceutical Research. 3(2):232-241.